The Federal Trade Commission recently announced the creation of a new Healthcare Task Force to coordinate the agency’s competition, consumer protection, economics, policy, and technology resources in the healthcare sector. The FTC described the initiative as a “coordinated, integrated approach” to enforcement and advocacy, reinforcing healthcare as a priority area for the agency.

The task force will draw from multiple FTC offices and is expected to work closely with other regulators, including the Department of Justice and the Department of Health and Human Services.

Key Takeaways

The announcement on March 20, 2026, highlights three important themes:

1. A broader enforcement lens. The FTC is continuing to move beyond traditional merger review to examine a wider range of conduct, including marketing practices, pricing and transparency, contracting arrangements, and technology-driven business models.

2. Centralized and coordinated oversight. By consolidating expertise across the agency, the Task Force is designed to identify investigations more quickly and pursue matters in a more coordinated manner, including alongside other enforcement bodies.

3. Sustained focus on healthcare markets. The FTC’s memorandum emphasizes concerns about consolidation, anticompetitive conduct, and deceptive practices that may increase costs or reduce access and quality.

Areas Under Scrutiny

The task force’s mandate spans the healthcare ecosystem, with implications for providers, payers, and healthcare companies.

For providers, the FTC is likely to continue scrutinizing mergers, affiliations, and other arrangements that may affect local competition, referral patterns, or patient access. Contracting practices and exclusivity provisions may also receive closer review.

For payers and pharmacy benefit managers (PBMs), the agency’s focus remains on pricing, rebates, network design, and consumer disclosures. Recent FTC activity suggests continued attention to transparency and out-of-pocket costs.

For device, biotech, and digital health companies, the FTC has signaled ongoing scrutiny of transactions, patent and exclusivity strategies, and health-related claims.

For consumer-facing healthcare and telehealth companies, marketing, billing, and subscription practices remain key enforcement areas, particularly where claims or pricing may be misleading.

Enforcement Trends

The FTC’s recent enforcement activity illustrates the breadth of its healthcare agenda. The agency has challenged medical-device transactions, pursued actions involving patent listings, and brought consumer protection cases involving insurance marketing, telehealth claims, and deceptive health products.

These actions reflect a dual focus on competition and consumer protection, which the task force is intended to formalize and expand.

For more information, please contact me or your regular Parker Poe contact. Click here to subscribe to our latest alerts and insights.